Supraphysiological Testosterone Therapy as Treatment for Castration-Resistant Prostate Cancer.

about

Supraphysiological Testosterone Therapy as Treatment for Castration-Resistant Prostate Cancer.

Item

http://www.wikidata.org/entity/Q55096243

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Supraphysiological Testosteron ...... ion-Resistant Prostate Cancer.

@en

Supraphysiological Testosteron ...... ion-Resistant Prostate Cancer.

@nl

type

Item

label

Supraphysiological Testosteron ...... ion-Resistant Prostate Cancer.

@en

Supraphysiological Testosteron ...... ion-Resistant Prostate Cancer.

@nl

prefLabel

Supraphysiological Testosteron ...... ion-Resistant Prostate Cancer.

@en

Supraphysiological Testosteron ...... ion-Resistant Prostate Cancer.

@nl

P1476

Supraphysiological Testosteron ...... ion-Resistant Prostate Cancer.

@en

P2093

Eva Corey

http://www.w3.org/2001/XMLSchema#string

Hung-Ming Lam

http://www.w3.org/2001/XMLSchema#string

P2860

Androgen-induced proliferative quiescence in prostate cancer cells: the role of AS3 as its mediator

Abiraterone in metastatic prostate cancer without previous chemotherapy

Novel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate Cancer

Expression of novel genes linked to the androgen-induced, proliferative shutoff in prostate cancer cells

Mechanism of androgen action on cell proliferation: AS3 protein as a mediator of proliferative arrest in the rat prostate

Increased survival with enzalutamide in prostate cancer after chemotherapy

Androgen-repressed phenotype in human prostate cancer.

Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients.

Androgen suppresses the proliferation of androgen receptor-positive castration-resistant prostate cancer cells via inhibition of Cdk2, CyclinA, and Skp2.

Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation.

P304

167

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FONC.2018.00167

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-05-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29872642

http://www.w3.org/2001/XMLSchema#string

P932

5972313

http://www.w3.org/2001/XMLSchema#string